ESG Report 2023

15 Products in R&D Products R&D Stage Olotadine Hydrochloride Eye Drops TUL01101 Tablets * Polyvinyl Alcohol Eye Drops Moxifloxacin Hydrochloride Eye Drops GLP-1 Oral Preparation* TUL01101 Tablets * Novel Recombinant Urate Oxidase * Osteoporosis Monoclonal Antibody Insulin Degludec/Liraglutide Liraglutide Injection Semaglutide Injection Insulin Degludec Injection Anti-IL-4R Monoclonal Antibody Ultra-long-acting Insulin Analogue * Semaglutide Injection Interleukin-2 Fusion Protein * Dual Target Hypolipidemic Drugs * LB2012* LB2023* LB2311* LB2249* Murpirocin Ointment Tadalafil Tablets Sodium Hyaluronate Eye Drops TUL12101 Eye Drops * LB1091* Insulin Degludec/Insulin Aspart TUL01101 Ointment * UBT251 * Injection Second-generation GI Hormones * Lp(a) Hypolipidemic Drugs * LB2236* LB2237* LB2332* Alendronate Vitamin D3 Tablets Levofloxacin Eye Drops Tiotropium Bromide Inhalation Spray Acetylcysteine Effervescent Tablets Crisaborole Ointment Fenelidone Tablets Multivitamin Tablets Indications Diabetes Osteoporosis Diabetes Eczema & Asthma Rheumatoid Arthritis Atopic Dermatitis Conjunctivitis Hyperlipidemia SLE, etc. Inflammatory Diseases Bacterial Infection Fat Loss and Muscle Gain Dermatosis Erectile Dysfunction Xerophthalmia IgA Nephritis Hyperuricemia & Gout Obesity Xerophthalmia Inflammatory Bowel Disease Atopic Dermatitis Diabetes, Obesity & NASH Obesity Hyperlipoproteinemia, etc. Nonalcoholic Steatohepatitis Hyperlipidemia Fungal Infection Chronic Pulmonary Obstruction Respiratory Infection Osteoporosis Diabetic Nephropathy Atopic Dermatitis Nutritional Supplements Production Application Clinical Trial Clinical Trial Application Preclinical R & D stage : * Class 1 new drugs Environmental, Social and Governance Report 2023 The United Laboratories International Holdings Limited Diabetes & Obesity